Univariate analysis of factors influencing OS after HSCT
| . | All patients who underwent transplantation . | Symptomatic patients . | Patients with first-line etoposide . | |||
|---|---|---|---|---|---|---|
| n . | OS (CI) . | n . | OS (CI) . | n . | OS (CI) . | |
| 3-y post-HSCT survival∗ | 75 | 88% (78%-94%) | 65 | 86% (75%-93%) | 52 | 85% (72%-92%) |
| Genetic diagnosis | ||||||
| FHL | 56 | 89% (78%-95%) | 49 | 88% (75%-94%) | 41 | 85% (70%-93%) |
| Hereditary non-FHL | 19 | 84% (58%-95%) | 16 | 81% (52%-94%) | 11 | 81% (45%-95%) |
| Remission† | ||||||
| Full | 51 | 90% (78%-96%) | 41 | 88% (73%-95%) | 33 | 88% (71%-95%) |
| Partial or no | 22 | 91% (68%-98%) | 22 | 91% (68%-98%) | 17 | 88% (61%-97%) |
| Time diagnosis to HSCT | ||||||
| <3 mo | 36 | 80% (63%-90%) | 34 | 79% (62%-90%) | 26 | 77% (56%-89%) |
| >3 mo | 39 | 95% (81%-99%) | 31 | 94% (77%-98%) | 26 | 92% (73%-98%) |
| Conditioning‡ | ||||||
| Busulfan based | 24 | 91% (71%-98%) | 18 | 89% (62%-97%) | 13 | 88% (57%-99%) |
| Treosulfan based | 41 | 88% (73%-95%) | 38 | 87% (71%-94%) | 30 | 83% (64%-93%) |
| Donor | ||||||
| Haploidentical | 9 | 44% (14%-72%)∗ | 9 | 44% (14%-72%) | 7 | 43% (10%-73%) |
| MMUD | 14 | 86% (54%-96%) | 13 | 85% (51%-96%) | 9 | 78% (36%-94%) |
| MRD and MUD | 52 | 96% (85%-99%) | 43 | 95% (83%-99%) | 36 | 94% (80%-99%) |
| . | All patients who underwent transplantation . | Symptomatic patients . | Patients with first-line etoposide . | |||
|---|---|---|---|---|---|---|
| n . | OS (CI) . | n . | OS (CI) . | n . | OS (CI) . | |
| 3-y post-HSCT survival∗ | 75 | 88% (78%-94%) | 65 | 86% (75%-93%) | 52 | 85% (72%-92%) |
| Genetic diagnosis | ||||||
| FHL | 56 | 89% (78%-95%) | 49 | 88% (75%-94%) | 41 | 85% (70%-93%) |
| Hereditary non-FHL | 19 | 84% (58%-95%) | 16 | 81% (52%-94%) | 11 | 81% (45%-95%) |
| Remission† | ||||||
| Full | 51 | 90% (78%-96%) | 41 | 88% (73%-95%) | 33 | 88% (71%-95%) |
| Partial or no | 22 | 91% (68%-98%) | 22 | 91% (68%-98%) | 17 | 88% (61%-97%) |
| Time diagnosis to HSCT | ||||||
| <3 mo | 36 | 80% (63%-90%) | 34 | 79% (62%-90%) | 26 | 77% (56%-89%) |
| >3 mo | 39 | 95% (81%-99%) | 31 | 94% (77%-98%) | 26 | 92% (73%-98%) |
| Conditioning‡ | ||||||
| Busulfan based | 24 | 91% (71%-98%) | 18 | 89% (62%-97%) | 13 | 88% (57%-99%) |
| Treosulfan based | 41 | 88% (73%-95%) | 38 | 87% (71%-94%) | 30 | 83% (64%-93%) |
| Donor | ||||||
| Haploidentical | 9 | 44% (14%-72%)∗ | 9 | 44% (14%-72%) | 7 | 43% (10%-73%) |
| MMUD | 14 | 86% (54%-96%) | 13 | 85% (51%-96%) | 9 | 78% (36%-94%) |
| MRD and MUD | 52 | 96% (85%-99%) | 43 | 95% (83%-99%) | 36 | 94% (80%-99%) |
A log-rank test was performed for evaluation of statistical differences between groups for all parameters.
TBI, total body irradiation.
∗Significant haploidentical donor vs nonhaploidentical (P < .001) and MMUD alone (P = .041).
6 patients are included with follow-up time after HSCT between 2.35 and 2.80 years.
2 answers of remission status missing, both patients died within 1 year after HSCT.
10 patients with other conditioning regimes (eg, melphalan-based and TBI).